

6 December 2019

## Tranche 1 Placement Funds Received

- First Subscription funds of \$2.4m have been received by the Company
- Shares to be allotted early next week
- Funds used to expand Meluka Health and Jenbrook business activities

EVE Investments (ASX:EVE), an ASX listed health, nutrition and wellness company, announces that Everhoney Biotech Australia Pty Ltd (“Everhoney”) and Hong Kong Jusheng Bolang Technology Co., Limited (“Jusheng Bolang”) have completed payment of their First Subscription funds under their respective Subscription Deeds.

The First Subscription raises \$2,411,145 at \$0.005, a Second Subscription will be issued within 3 months of the execution of the Subscription Deeds and raises a further \$6,888,986 at \$0.01. Both subscriptions were overwhelmingly approved at the Company’s recent Annual General Meeting. AGC Capital, a Sydney-based financial services firm, which specialises in advising on IPOs, funds management and corporate finance activities acted as EVE’s advisor to the subscription.

Shares will be allotted to both parties early next week.

### *Subscribing Parties*

Everhoney Biotech Australia Pty Ltd is an investment company based in Sydney with interests across a broad range of industries both domestically and internationally with a focus on agriculture, health and nutrition businesses in Australia. The company continues to build successful, professional relationships across a broad range of interests in the investment community.

Hong Kong Jusheng Bolang Technology Co., Limited is an international trading enterprise based in Hong Kong and specialising in trading various high-quality health products. The company has a well-developed business network providing a bridge between Australia and Asia.

### *Use of Funds*

The Company will utilise the proceeds from the First Subscription to build inventory of its Meluka range of products including the existing honey range, essential oil range and the recently formulated bio-fermented honey drink. Product builds are intended for sale in the key markets of China, the United States and Australia. The product build has already commenced with manufacturing continuing and shipments expected to commence in late-December.

### **For more information:**

Bill Fry  
Executive Director  
Eve Investments Ltd  
+61 8 6465 5500  
[billf@eveinvestments.com.au](mailto:billf@eveinvestments.com.au)

For personal use only

### **About EVE Investments**

EVE Investments invests in companies with a focus on the medical nutrition and wellness sector. The Company's investment strategy has a three pronged approach.

1. To invest in businesses that are in the early growth phase with the aim to support their expansion programs.
2. To identify products that have unique medicinal properties and a global reach application.
3. Preference for natural organic products that have demonstrated medicinal benefits.

For further information, please visit [www.eveinvestments.com.au](http://www.eveinvestments.com.au) and follow us on Twitter [@EVEInvestments](https://twitter.com/EVEInvestments)

For personal use only